Savillex, LLC has completed its acquisition of Entegris, Inc.'s Life Sciences Fluid Management business, the Eden Prairie, Minnesota-based maker of high-purity fluid handling products said. Financial terms were not disclosed.
The acquired portfolio covers bioprocessing and pharmaceutical manufacturing solutions, including Aramus and PE bags, single-use assemblies and components used in discovery, clinical and commercial manufacturing. Savillex said the addition broadens its life sciences offerings with a larger set of high-performance single-use products.
Products and team
Along with the product lines, Savillex takes on the fluid management unit's team and its technologies in high-purity fluid management. The company said customers can expect expanded single-use options, more technical expertise and added capabilities spanning early-stage research through commercial production. Combining the two businesses is intended to help customers simplify increasingly complex bioprocessing workflows, according to Savillex.
The acquired lines sit alongside Savillex's own Savillex, Containment and Bioprocessing offerings.
Executive comment
Chief executive officer Eric Giesing said the Life Sciences Fluid Management business has built a strong reputation in high-purity single-use bioprocessing, and that the Aramus product line fits naturally alongside Savillex's existing offerings. He said the deal expands the portfolio and lets the company offer a wider range of solutions to biopharmaceutical and pharmaceutical customers. Giesing added that Savillex is excited to welcome the team behind the business and will keep investing in technologies that help customers accelerate development and production of critical therapies.
Chris Bedi, general manager of fluid management at Savillex, said the acquisition creates an opportunity to bring a broader portfolio of high-value fluid management solutions to pharmaceutical and biopharmaceutical customers worldwide. He said the fluid management portfolio complements Savillex's existing capabilities, and that the combined company will continue to provide innovative solutions while expanding support for partners across drug development.
Strategy and advisors
Savillex described the acquisition as a further step in its strategy of delivering industry-leading solutions for the life sciences market. The company said it remains committed to investing in innovation, quality and customer partnerships as it expands its portfolio to meet the needs of biopharmaceutical and pharmaceutical manufacturers worldwide.
EC M&A of New York acted as financial advisor to Savillex, and Sidley Austin LLP of Chicago served as legal counsel.